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Use of Cefotaxime and Metronidazole for Treating 
Cerebral Abscesses
Sir— In 1993, Sjölin et al. reported the cases of 15 patients with
years, an ultimately fatal underlying disease, an initial clinical 
status of critical illness, coma, or inadequate antibiotic treat­
ment [4],
In the past several years we detected a rise in the incidence of
brain abscesses who were treated with cefotaxime and metronida- infection due to group A streptococci that cannot be as effectively 
zole and noted that cefotaxime had rarely been reported as a treat- treated with cefotaxime and metronidazole as with penicillin G 
ment for cerebral abscesses [11.
Since 1983, we have empirically used the combination of cefo­
taxime and metronidazole as the initial treatment for cerebral ab-
since the activity of cefotaxime against group A streptococci was 
lower than that against penicillin G; this rise may be due to the 
massive use of quinolones and third-generation cephalosporins for
scesses; this treatment has been based on the most likely focus of treating general infections. Thus, we believe that an individualized
infection, the epidemiologic changes in the infections in our area treatment approach and follow-up with serial CT scans is required
and in our hospital [2], and our common sense antibiotic use in cases where penicillin or ampicillin plus chloramphenicol con-
policy [3].
In one study published in 1991 [4], we compared 35 adult pa­
tients with cerebral abscesses who received a standard treatment 
with 31 patients who were treated with cefotaxime and metronida­
zole. In the group treated with cefotaxime and metronidazole, there 
were higher rates of success and no significant differences in mor­
tality or recurrences of abscesses, although there were fewer com­
plications and there was lower mortality in the group treated with 
cefotaxime and metronidazole.
The total mortality in our study was 14%, whereas there were 
no deaths in the study by Sjölin et al. [1]; these differences in 
mortality were probably related to the fact that the patients had 
different types of disease and different types of complications. In 
our study, higher mortality was associated with an age of >40
Reprints or correspondence: Professor J. Gómez, Plaza de la Cruz Roja 3, 
1C, 30003 Murcia, Spain.
Clinical Infectious Diseases 1995;21:708
© 1995 by The University of Chicago. All rights reserved.
1058-4838/95/2103 -0054S02.00
tinue to be the antibiotics of choice for patients with cerebral 
abscesses.
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Viral Antibodies in Chronic Fatigue Syndrome
Sir— In his article on viral antibodies in chronic fatigue syndrome 
(CFS), Manian [1] stated that patients with CFS frequently have 
elevated levels of IgG antibody to the viral capsid antigen (VCA) 
of Epstein-Barr virus, or elevated levels of antibody to coxsackie­
virus BI or coxsackievirus B4. As Manian points out in his discus­
sion, the outcome may have been biased by the fact that the sero­
logical tests of patients and controls were not performed concur­
rently. This is an important point, as we have found significant
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differences in levels o f IgG antibody to VCA and EA between 
patients with CFS and matched controls (IgG levels were elevated 
in patients with CFS), which disappeared after concurrent testing 
of the samples from patients with CFS and from controls (our 
unpublished observation).
Not only is concurrent testing of samples relevant, but concur­
rent collection of the serum samples is important as well. Enterovi­
rus infections are subject to seasonal and geographic variation. 
This implies that serum samples from controls should be collected 
at the same time that those from patients are collected and that 
controls should be matched with the patients for domicile. When 
we followed such guidelines, we found no differences in levels of 
antibody to enteroviruses between patients with CFS and controls 
as well as no differences in levels of antibodies to coxsackie B 
viruses [2].
We also disagree with Manian’s observation of elevated levels 
of CF antibody to coxsackieviruses. First, the CF antibody re­
sponse to viruses that are closely antigenically related will not be 
type specific and may be affected by the “ doctrine of original
CID 1995;21 (September) Correspondence 709
antigenic sin,” thus actually revealing antibody to a childhood 
infection.
Furthermore, the statistical analyses applied in Manian’s study 
do not seem appropriate. In the case of ordinal variables (as in 
immunofluorescence testing) and nonnormal distribution, nonpara- 
metric testing should have been applied.
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Reply
Sir— We appreciate the comments of Swanink et al. regarding 
our recent article [1]. First, as we discussed in our article, we 
realize that concurrent serological testing of the case patients and 
controls would have been ideal. However, we are not sure why 
our results would necessarily be “ biased” toward finding higher 
titers of antibody to certain viruses in the cases than in the controls 
when this was not done. Swanink et al.’s unpublished observation 
regarding the loss of significant differences in elevated levels of 
IgG antibody to Epstein-Barr virus capsid antigen (EBV VCA) 
and early antigen between patients with chronic fatigue syndrome 
and matched controls when concurrent testing was used is interest­
ing. We look forward to their publication of these findings along 
with a possible explanation.
Second, we realize that enteroviral infection may be seasonal 
and subject to geographic variation. However, it is interesting that 
even though our controls were tested during two peak months 
(July and August) for enteroviral infection in the United States 
[2], as a group they did not have higher antibody titers against any 
of the enteroviruses tested when compared with the case patients. 
Because the case patients were tested throughout the year, any 
potential bias in comparing enteroviral antibody titers of these 
groups should have favored the finding of higher titers in the 
controls rather than in the case patients. However, when there was
a significant difference in the enteroviral antibody titers between 
the case patients and controls, higher titers were always found in 
the case patients. We think that geographic variation may also help 
to explain the difference between our findings and those of Swan­
ink and colleagues.
Third, Swanink etal. the type specificity of CF antibody
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to enteroviruses. Although some cross-reaction may occur, it is 
interesting that of the 19 cases in which significant titers of anti­
body (5= 1:8) were found to at least 1 of the 10 coxsackie viruses 
tested (4 type A and 6 type B) in our study, the majority (68%) 
had concurrent significant antibody titers to only 4 or fewer viruses. 
Therefore, the degree of cross-reactivity, at least based on the 
findings in our study, did not appear to be inordinately high. More­
over, the problem with cross-reactivity should have equally af­
fected the sera from the controls, since the same laboratory per­
formed the tests. The statement regarding “ the doctrine of original 
antigenic sin”  is not fully correct, as CF (as opposed to neutraliz­
ing) antibodies to enteroviruses usually can be detected only for 
a few months after onset of infection [3],
Finally, concerning the statistical analysis, a t test was used for 
comparison of geometric means of antibody titers between the 
two groups. However, because of the possibility of a significant: 
difference in the variances between the case patients and controls, 
we used the more conservative Welch’s alternate /-test, which, as 
opposed to the standard /-test, does not assume equal variances 
[4], Of note, significantly higher antibody titers to EBV VCA in 
the case patients vs. the controls were also found, even when the 
data was analyzed by a different method (Fisher’s exact test).
Farrin A. Manian
St. John 'V Mercy Medical Center, St. Louis, Missouri
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